ClinicalTrials.gg

Program

SYS6006 COVID-19 vaccine

Also written as “20 μg dose of SYS6006”, “30 μg dose of SYS6006” and “SYS6006”.

Its studies are mostly in COVID-19, led by CSPC Pharmaceutical Group.

Furthest: phase 2, since Jun 27, 20224 company-led studies, 4 open or runningNext primary completion: Dec 31, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
CSPC Pharmaceutical Group44 open or runningphase 2since Jun 27, 2022Apr 28, 2022Dec 31, 2028phase 2 · NCT07622225

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 28, 2022First studies: 2 phase 1 studies in SARS-CoV-2First studyNCT05354089, NCT05354063
  2. Jun 27, 2022Phase 2 study in COVID-19NCT05439824 · 450 enrolled · China
  3. May 17, 2026Phase 2 study in Advanced Solid TumorsNCT07622225 · 264 planned

Ahead

  1. Dec 31, 2028Primary completion: phase 2 study in Advanced Solid TumorsNCT07622225

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07622225Advanced Solid Tumors2Not yet recruitingDec 31, 2028264
NCT05439824COVID-19 · China2Active, not recruitingJan 12, 2023450
NCT05354089SARS-CoV-2 · China1Active, not recruitingJul 9, 202240
NCT05354063SARS-CoV-2 · China1Active, not recruitingSep 5, 202240

How it is read

Names in the registry

  • “20 μg dose of SYS6006”, 2 entries
  • “30 μg dose of SYS6006”, 2 entries
  • “SYS6006”, 1 entry
  • “SYS6006 20 μg”, 1 entry
  • “SYS6006 30 μg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.